Key Developments in Obesity Management in 2023:
- Recognition of Obesity’s Complexity: The American Academy of Pediatrics acknowledged the multifaceted nature of pediatric obesity and the need for a broad range of treatments.
- Introduction of New Medications: The year saw the introduction of the first-ever triple agonist and a high-potency oral GLP1 agonist, marking significant advancements in obesity treatment.
- Updated Clinical Practice Guidelines: The American Academy of Pediatrics released its first updated clinical practice guideline in 15 years, embracing a full range of treatment modalities for pediatric obesity, including lifestyle changes, pharmacotherapy, and metabolic and bariatric surgery.
- Innovations in GLP1 Agonism: Previously, high-potency GLP1 agonism was only available in injectable form. However, the oral GLP1 agonist orforglipron demonstrated similar efficacy to its injectable counterparts.
- Triple-Agonist for Weight Loss: The triple-agonist, targeting glucose-dependent insulinotropic polypeptide, GLP1, and glucagon receptors, showed higher total body weight loss than any previous agent in a phase II clinical trial.
- Shift in Treatment Perspectives: There has been a significant shift in scientific and public discourse towards considering treatments beyond behavioral techniques for obesity. This is mainly due to the interest in GLP1 agonists.
- Addressing Weight Stigma: Weight stigma, a significant barrier in obesity care, is being addressed more effectively, paving the way for better treatment and care for those with obesity.
Insights and Future Directions:
- Comprehensive Treatment Approaches: The recognition of obesity as a complex condition necessitates a comprehensive approach to treatment, combining lifestyle, medication, and surgery.
- Potential of GLP1 Agonists: The advancements in GLP1 agonist treatments, both injectable and oral, open new avenues for effective obesity management.
- Overcoming Weight Stigma: Addressing weight stigma is crucial for improving care and treatment for individuals with obesity, indicating a more inclusive and understanding approach in the medical community.